Alberta sees another measles spike; province now has 287 confirmed cases
Alberta continues to see a sharp rise in measles cases.
As of Tuesday, Alberta has 287 confirmed measles cases—22 more cases than the day before.
Seventeen of the new cases are in the province's south zone.
There are no new cases in the Calgary area.
After months of pressure from medical experts, Alberta Health announced on Monday it was beefing up its measles campaign.
In the coming days, there will be more vaccination clinics across the province.
A hotline is also launching for Albertans wanting to check their vaccination status or learn more about the highly contagious—and preventable—disease.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
39 minutes ago
- Globe and Mail
Should You Buy Eli Lilly Stock Before June 22?
(NYSE: LLY) stock hasn't been doing too well this year, but that could change later this month. A couple of key events are on the horizon this month during which the company will release new data from studies relating to multiple GLP-1 drugs. They can give investors insights into how well the drugs are doing, and whether approvals for new drugs and indications could be forthcoming in the near future. If Eli Lilly presents strong data, the stock could be set to rally and potentially be on a path to reaching new highs. Should you invest in this top healthcare company before June 22? Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Eli Lilly to present data on multiple drugs later this month The American Diabetes Association (ADA) is hosting its 85th Scientific Sessions event in Chicago later this month, from June 20 to 23. Eli Lilly will report on data from studies related to multiple GLP-1 drugs, including tirzepatide (already approved for weight loss and diabetes under the Zepbound and Mounjaro brands), orforglipron (its oral weight-loss medication), and retatrutide -- one of the most promising GLP-1 treatments in the company's pipeline. On June 22, Eli Lilly will also be hosting an investor event which will go over key presentations from the ADA Scientific Sessions. For investors, there will be a lot of important data to unpack from all this. Encouraging data from key drugs could help lift shares of the company, as it may give investors reason to be bullish on further drug approvals, which would lead to stronger growth prospects for Eli Lilly and greater upside for the stock. The stock has struggled this year As of the end of last week, shares of Eli Lilly were flat since the start of 2025. There hasn't been a catalyst to send the stock soaring. While it has reached highs of more than $900 this year, fears of healthcare reform and a slowdown in the economy appear to be weighing on its valuation. Plus, with the stock trading at more than 60 times its trailing earnings, there can't be any hiccups along the way for Eli Lilly. At that high of a multiple, investors are going to be demanding near perfection from the business. However, Eli Lilly has been performing well. In the trailing 12 months, it has generated revenue of more than $49 billion, and its profits on that have totaled $11.1 billion. Just a few years ago, in 2022, this was a business that was only bringing in less than $29 billion in revenue. Its profit that year was much more modest at $6.2 billion. The growth in its new GLP-1 drugs has transformed the business in a strong, positive way. And that's why strong and impressive data from the upcoming ADA event could be what gets the stock rallying again. Should you buy Eli Lilly before June 22? Eli Lilly is a strong and robust business, with some promising growth prospects on the horizon. This is a stock I firmly believe can reach a $1 trillion valuation within the next few years, given just how much growth it may achieve. And if that's the case, its upside could be more than 45% from where it is today. While its year-to-date returns look unimpressive, this is a stock that has a lot more room to rise higher. Although Eli Lilly may not be the cheapest stock to own, a premium looks justifiable when factoring in the company's recent results and future growth opportunities. Buying it before the upcoming ADA event, which may light a fire under its valuation, could be a great move for investors in the long run. Should you invest $1,000 in Eli Lilly right now? Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $660,341!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $874,192!* Now, it's worth noting Stock Advisor 's total average return is999% — a market-crushing outperformance compared to173%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
CBC
an hour ago
- CBC
How close are we to getting a vaccine for Lyme disease?
Diana Moser has, to the best of her knowledge, not contracted Lyme disease, a welcome status quo that might be credited to the tick-repellant clothing she wears in the yard of her East LaHave, N.S., home, or to the insect spray she squirts on herself, or to just plain-old luck. Or, it's possible the good fortune is due to what some are hoping is a "game changer" in the fight against the disease, which is caused by tick-borne bacteria and, if left untreated, can lead to severe heart, joint and nervous system symptoms. Moser is one of dozens of people in Nova Scotia, and more than 9,000 in the eastern United States, Eastern Canada and parts of Europe, who are taking part in clinical trials for a vaccine against Lyme infection. "I think it's incredibly important to have," she said of a vaccine, noting she knows at least four people who have contracted Lyme disease, including one who has had it multiple times. "It's such a tricky disease, like when you get Lyme, so many things can happen. It causes joint pain, it causes inflammation. It really affects your system in a deep and abiding way." There were more than 27,000 cases of Lyme disease recorded in Canada between 2009 and 2024, the majority of those in the last four years. Actual infection rates are higher, however, because cases go undetected or unreported, according to the federal government. In the United States, over 89,000 cases were reported in 2023 to the Centers for Disease Control. In one study, researchers used insurance claims data to estimate that nearly half a million people a year may be diagnosed and treated for Lyme disease. The vaccine furthest along the research pipeline is the collaboration between multinational pharmaceutical giant Pfizer and European vaccine company Valneva SE, with Phase 3 clinical trials scheduled to run to the end of December. WATCH | How close are we to getting a vaccine for Lyme disease?: As recorded cases of Lyme disease rise, so do hopes for a vaccine 6 minutes ago Duration 2:37 A Pfizer spokesperson said if trials are successful the company could potentially apply in 2026 to the U.S. Food and Drug Administration and the European Medicines Agency for approvals to market the vaccine. There is no timeline for a similar application to Health Canada. The clinical trials have targeted areas where Lyme disease is endemic. Participants were chosen for their increased risk, including landscapers in tick-infested areas, people who do a lot of hiking or gardening, or who have dogs that routinely come home with ticks attached. Like all participants, Moser doesn't know if she has been injected with a course of the real vaccine and a booster, or simply been given a placebo, although she hopes to learn which it is once the trials end. Some, but not all, blacklegged ticks carry Borrelia burgdorferi, the bacteria that causes Lyme disease. The ticks are tiny, living in woods, shrubs and long grass, attaching themselves to humans or animals that brush past the vegetation and then feeding on their blood. When they bite, some of their stomach contents, including the bacteria, are eventually discharged into the bloodstream. In most cases, the tick must be attached for at least 24 hours before a person is infected. The Pfizer-Valneva vaccine prompts the human body to create antibodies to a protein on Borrelia burgdorferi, according to Dr. Joanne Langley, a pediatrician with the Canadian Center for Vaccinology, a Halifax-based group helping conduct the clinical trials in Nova Scotia. Ideally, if a Borrelia burgdorferi -carrying tick latches on to the skin, the vaccinated immune system will recognize the bacteria and attack and clear it, preventing Lyme disease, Langley said. "It could be really a game changer for how we try to deal with Lyme infection," she said in an interview, adding that half of people who contract the disease don't even remember being bitten by a tick. "It would be really great if we could be a little more carefree in the woods and just walking around our environment." Found widely in the eastern United States, the first colony of blacklegged ticks in Canada was discovered in the 1970s in an Ontario provincial park on Lake Erie. It has since become established in six provinces. In Nova Scotia, which has some of the highest tick numbers, populations are growing both in rural and urban areas, according to the provincial government. What has perplexed some people who ritually pick ticks off their pets or who have been infected with Lyme is why it has taken so long to develop a vaccine, especially given Lyme vaccines for dogs have been available for years. A Lyme vaccine for humans did hit the market in 1998, but was pulled in 2002 by the company that developed it, citing poor sales. Its reputation had been damaged by reports of adverse reactions, even though the FDA didn't find any evidence it was causing harm. Thomas Hart, a microbiologist who studies Lyme disease at Johns Hopkins Bloomberg School of Public Health in Baltimore, said the controversy "just chilled the whole field." "That's part of why we're only now seeing momentum again and bringing the Lyme disease vaccine actually through clinical trials in to market," he said. Hart has not been involved with the Pfizer-Valneva work, but said it's a "real promising vaccine" and it will be a "big deal" if approved. But it's not the only vaccine research. For instance, Hart said, scientists are examining vaccines aimed at deterring ticks from simply feeding on humans, protecting people not just against Lyme disease, but from other tick-borne infections. Another strain of research attacks the problem from an imaginative angle — small food-like pellets coated in vaccine to inoculate, of all things, mice. It's an idea conceived by Dr. Maria Gomes-Solecki, a veterinarian and microbiologist at the University of Tennessee Health Science Center. Mice and ticks, she said, infect each other with Borrelia burgdorferi. Vaccinating mice attempts to break the cycle. That brings down the prevalence in an area of ticks that have the bacteria, which in turn cuts the risk of humans getting Lyme disease. "One strategy alone is not enough to control this disease," she said in an interview. The company US Biologic has been marketing the product for about a year and a half, according to president Chris Przybyszewski. Pellets can tossed using a scoop — at intervals at the sides of trails, for instance — or deployed near homes in small circular "stations." The product is aimed at homeowners, golf courses, summer camps, outdoor athletic facilities and pest-management outfits. The company is also working with governments to deploy it on public lands, he said. The pellets, shaped like acorns, don't provide any nutritional value and don't attract other animals, Przybyszewski said. But the mice will eat them, he said, and research shows they can cut the rate of infected ticks in an area by 75 per cent. There are plans to eventually bring the product to Canada, he said, with US Biologic likely to begin seeking approval this year or next. "I think it's just incredibly important that we pay more attention to this kind of concept, really focusing on products and programs that can make a difference and really create a new way of stopping infectious diseases," he said. For Colin Chase, a participant in the Pfizer-Valneva vaccine clinical trials, ticks are a fact of life, both as someone with a deep love of the woods, and as a volunteer search and rescuer who routinely clambers through dense Nova Scotia forests. Searchers take the full range of precautions, he said, examining each other for the tiny creatures, stripping down before they go inside their homes and throwing their clothes in the dryer and then the washer. Many have a favoured anti-tick spray they swear by. But even with those efforts, ticks can still sneak in and become embedded on the skin. If a vaccine is safe and effective, Chase said, why wouldn't someone take advantage? "Because otherwise the alternative is, 'Oh, I'm not going to go in the woods. I'm going to disconnect myself from the natural environment.' And there's so much beauty in the woods," he said.
Globe and Mail
2 hours ago
- Globe and Mail
Letters to the editor, June 11: ‘The obsession with NATO's 2-per-cent defence spending target ignores another global responsibility'
Re ''Nation-building' projects should also reflect Canadian values' (June 10): As a registered nurse who has practiced in both the United States and Canada, I would never trade our imperfect but equitable universal health care for the ragged patchwork quilt of American health care that leaves many with no coverage whatsoever. We should act to strengthen the health care system that sustains us all. As a health care worker with a deep concern for planetary health, I also echo the concern that nation-building must be undertaken by investing in programs that make people healthier. Building more pipelines would add to our carbon emissions and worsen climate change, darkening our chances for overall well-being and a healthy future. Agnes Black RN; New Westminster, B.C. Canada accounts for less than 2 per cent of global greenhouse gas emissions. While we should do our part to reduce emissions, I do not believe halting pipeline projects will prevent wildfires or significantly change global outcomes, especially while countries such as China and India continue expanding coal use. Pipelines are the safest and most efficient way to transport the oil and gas our society still depends on. Until a reliable, affordable, large-scale alternative to fossil fuels exists – and we are nowhere close – oil and gas will remain essential. Cutting off pipeline infrastructure wouldn't stop demand, just shift transportation to rail or truck, which are riskier and more carbon-intensive. Wildfires are caused by a combination of factors: lightning, human carelessness, forest mismanagement and climate trends. Suggesting that pipelines 'bring fires' seems to ignore the complexity of the issue and undermines serious conversations about adaptation, fire prevention and energy transition. Kevin Kobes Lloydminster, Alta. Columnist André Picard advocates selection of nation-building projects to strengthen medicare and extinguish HIV-AIDS, in accordance with the Canadian values described in Mark Carney's 2021 book Value(s). I agree, but first we should have major projects that contribute to national prosperity and economic resiliency, while respecting Indigenous reconciliation and climate change. Bottom line: There is a price attached to solidarity, fairness, responsibility, resilience, sustainability, dynamism, humility and even compassion. Virtue-signalling is morally vacuous and valueless until we enable ourselves to put our money where our mouth is. As Mr. Carney also says, we can't redistribute what we don't have. Ellen Anderson Summerside, PEI Re 'Carney lays out defence boost, says era of U.S. dominance over' (June 10): The obsession with NATO's 2-per-cent defence spending target ignores another global responsibility: foreign aid as a share of national income. If we want to build a safer, more stable world, we should prioritize lifting people out of poverty, not just boosting defence budgets. Countries such as Sweden, Luxembourg and Norway routinely exceed the United Nations' target of 0.7 per cent of gross national income for aid. Canada, though still falling short at between 0.34 and 0.38 per cent, gives a much higher share than the United States, which contributes less than 0.24 per cent, and that number is set to fall even further under the Trump administration. If NATO members matched defence rhetoric with real investment in global development, they would be far more effective in addressing and reducing the root causes of conflict and creating lasting security. I thought that was the end goal anyway. Am I wrong? Timothy Kwiatkowski London, Ont. Re 'Carney should know it's way too soon to invite Modi to Canada' (June 7): I thought Mark Carney was a Blue Liberal in the tradition of Paul Martin, but he is doing what Stephen Harper recommended recently regarding India. Narendra Modi's attitude toward Sikhs is part of his vision of Hindu chauvinism, which targets minorities. His repression in Muslim-majority Kashmir flows from the same vision. Mr. Modi must be mighty pleased that Canada seems to be disregarding not just his interference in Canada, but also his repressive policies and actions, including toward the press. Masud Sheikh Oakville, Ont. Canada's G7 invitation to Narendra Modi has understandably generated debate, given the allegations linking Indian agents to violence on Canadian soil. These accusations must be taken seriously, but it is important to remember the facts have yet to be determined in court. As host, Canada faces the challenge of balancing bilateral concerns with India and broader international responsibilities. The G7 is a forum for the world's largest economies and leading democracies to address global issues. India, as the world's largest democracy and fifth-largest economy, is an important partner in this context. By inviting Mr. Modi, I believe Canada is not ignoring unresolved bilateral issues, but rather recognizing they should not overshadow the G7's multilateral purpose. Canada is a strong supporter of multilateral dialogue and a rules-based international order. Engaging India at the G7 is consistent with these values and ensures the summit remains relevant and effective in today's interconnected world. Stewart Beck Former Canadian high commissioner to India; North Vancouver Re 'Industry Minister Joly signals action on steel dumping into Canada coming' (Report on Business, June 7): Please forgive my failing memory, but aren't these now foreign-owned steel companies – presently criticizing the government over the lack of tariffs on steel dumping to support the floor on domestic prices – the same group that, a few decades ago, admonished the government of the day for interfering with the global market by restricting foreign ownership of critical infrastructure industries? Stephen Halman Toronto Re 'Some university professors say AI is here to stay, so students should learn how to use it'(June 4): I thought the point of going to school and receiving an education was so students would be able to understand complex language, by looking up the meaning of words so they can converse in the terminology of their chosen discipline of study. In the future, are people going to walk around asking artificial intelligence to translate everything for them, because they are too lazy to learn the meaning of words, concepts and issues? Kim Patrick O'Leary Vancouver Re 'For Trump, the L.A. protests are an opportunity to wield power and spread fear' (June 10): It was 55 years ago when the Ohio National Guard was called to Kent State University where, on a U.S. campus peacefully protesting the war in Vietnam, four young people were shot dead by guardsmen. Soon after, Neil Young wrote: 'Tin soldiers and Nixon coming / We're finally on our own / This summer I hear the drumming; Four dead in Ohio.' Will the lyrics need to be altered? 'Tin soldiers and Trump coming / How many dead in greater L.A.?' Heather MacAndrew Victoria Letters to the Editor should be exclusive to The Globe and Mail. Include your name, address and daytime phone number. Keep letters to 150 words or fewer. Letters may be edited for length and clarity. To submit a letter by e-mail, click here: letters@
